Core Insights - The Hong Kong Technology ETF (513560) has seen a significant increase, with a nearly 2% jump on September 11, 2025, marking its fourth consecutive rise and reaching a new high since its inception [1] - The ETF has achieved an impressive 88.27% net value increase over the past year, ranking first among comparable funds [2] - The underlying index, the CSI Hong Kong Stock Connect Technology Index, consists of 50 large-cap technology companies with high R&D investment and revenue growth, reflecting the overall performance of technology leaders in the Hong Kong Stock Connect [2][5] Performance Comparison - The CSI Hong Kong Stock Connect Technology Index has outperformed other indices, with a cumulative increase of 60.63% from 2018 to September 11, 2025, compared to 6.11% for the Hang Seng Technology Index and 0.56% for the Hong Kong Stock Connect Internet Index [2][3] - Over the past year, the CSI Hong Kong Stock Connect Technology Index has increased by 90.96%, while the Hang Seng Technology Index rose by 70.64% [3] Fund Details - As of September 11, 2025, the Hong Kong Technology ETF has reached a size of 770 million yuan, with 520 million shares outstanding, both marking new highs since its establishment [5] - The ETF has seen a net inflow of 8.89 million yuan recently, with a total of 58.60 million yuan net inflow over the past five trading days [5] Market Trends - The U.S. investors' interest in the Chinese market has reached its highest level since 2021, particularly in areas like humanoid robots, biotechnology, and drug development [4] - The Hong Kong internet sector is highlighted for its potential due to self-developed AI chips and cloud business expansion, alongside attractive valuations and improving asset quality [4]

Core Viewpoint - The A+H innovative drug sector is experiencing a rebound, with significant gains in both A-share and Hong Kong-listed ETFs focused on innovative drugs, indicating strong market confidence despite recent negative news from the U.S. regarding potential restrictions on Chinese pharmaceuticals [1][3]. Market Performance - The Hong Kong innovative drug ETF (520880) has seen a net subscription of over 160 million yuan in a single day, continuing a streak of eight consecutive days of inflows totaling nearly 350 million yuan [3]. - Major players in the Hong Kong innovative drug sector, such as BeiGene and CanSino Biologics, have reported gains exceeding 4%, while smaller companies like Jiateng Biopharma-B have surged over 17% to reach a historical high [1][3]. Industry Trends - The fund manager of the Hong Kong innovative drug ETF (520880) expressed confidence that U.S. restrictions on Chinese innovative drugs are unlikely to be implemented, citing that multinational corporations (MNCs) have already procured over 90 billion USD worth of Chinese innovative drug patents from January to August this year [3][4]. - The ETF has undergone a "purification" adjustment, completely removing CXO companies and focusing solely on innovative drug R&D firms, which is expected to enhance its performance in the sector [4]. Investment Insights - The recent market volatility may present a buying opportunity for high-quality innovative drug stocks, as the ETF is positioned to capitalize on potential rebounds in the sector [4]. - The Hong Kong innovative drug ETF (520880) has achieved a year-to-date increase of 119.75%, outperforming other indices in the same category prior to the recent adjustments [4][5].

Core Insights - 康方生物's stock rose over 4%, specifically 4.39%, reaching 133.3 HKD with a trading volume of 288 million HKD [1] Group 1: Clinical Research Results - 康方生物's overseas partner, Summit Therapeutics, presented updated data from the global multicenter Phase III HARMONi study at the 2025 WCLC Presidential Symposium, indicating an improvement in overall survival (OS) with a hazard ratio (HR) of 0.78 (P=0.0332) [1] - The updated OS data shows a positive trend compared to the analysis from May, particularly highlighting a significant benefit in the North American population with an HR of 0.70 [1] Group 2: Clinical Performance and Market Value - 中信建投 noted that both the international Phase III HARMONi study and the Phase III HARMONi-A study conducted in China demonstrated excellent clinical performance in progression-free survival (PFS) and OS [1] - The results confirm that the依沃西 therapy not only has rapid efficacy and effective disease control but also exhibits a favorable tail effect in tumor immunotherapy, emphasizing its consistent benefits and safety across different regions and ethnicities [1]

Core Viewpoint - 康方生物's stock rose over 4%, reaching 133.3 HKD with a trading volume of 288 million HKD, following the release of updated data from the HARMONi study at the 2025 WCLC conference [1] Group 1: Clinical Study Results - 康方生物's partner, Summit Therapeutics, presented updated data from the global multicenter Phase III HARMONi study, showing an improvement in overall survival (OS) with a hazard ratio (HR) of 0.78 (P=0.0332) [1] - The updated OS data indicates a positive trend compared to the analysis from May, particularly highlighting a significant benefit in the North American population with an HR of 0.70 [1] Group 2: Treatment Efficacy - 中信建投 noted that the HARMONi study results, along with the Phase III HARMONi-A study conducted in China, demonstrated excellent clinical performance in both progression-free survival (PFS) and OS [1] - The findings confirm that the依沃西 therapy offers rapid efficacy and effective disease control, along with a favorable tail effect in tumor immunotherapy [1] Group 3: Global Market Potential - The consistent benefit trends and safety profiles observed in both global and Chinese clinical settings further emphasize the global market value of 依沃西 [1]

Key Points - The top three companies with net inflows of southbound funds are Alibaba-W (09988) with 4.234 billion, Ping An of China (02318) with 844 million, and Southern Hang Seng Technology (03033) with 480 million [1] - The top three companies with net outflows of southbound funds are Xiaomi Group-W (01810) with -1.733 billion, Meituan-W (03690) with -852 million, and Kangfang Biologics (09926) with -462 million [1] - In terms of net inflow ratio, Tehai International (09658) leads with 62.75%, followed by Yancoal Australia (03668) with 51.59%, and Yimeng Biologics-B (09606) with 51.01% [1] - The companies with the highest net outflow ratios are GX China (03040) at -100.00%, Kangji Medical (09997) at -60.98%, and China International Marine Containers (02039) at -48.45% [1] Top 10 Net Inflows - Alibaba-W (09988) had a net inflow of 4.234 billion, representing a 16.56% increase in closing price to 141.900 [2] - Ping An of China (02318) saw a net inflow of 844 million, with a 24.06% increase in closing price to 57.200 [2] - Southern Hang Seng Technology (03033) recorded a net inflow of 480 million, with a 6.20% increase in closing price to 5.715 [2] Top 10 Net Outflows - Xiaomi Group-W (01810) experienced a net outflow of -1.733 billion, with a -17.96% decrease in closing price to 56.200 [2] - Meituan-W (03690) had a net outflow of -852 million, with a -5.77% decrease in closing price to 99.650 [2] - Kangfang Biologics (09926) faced a net outflow of -462 million, with a -15.64% decrease in closing price to 140.100 [2] Net Inflow Ratios - Tehai International (09658) had a net inflow ratio of 62.75% with a net inflow of 7.0962 million, closing at 14.980 [3] - Yancoal Australia (03668) recorded a net inflow ratio of 51.59% with a net inflow of 28.6046 million, closing at 27.620 [3] - Yimeng Biologics-B (09606) had a net inflow ratio of 51.01% with a net inflow of 194 million, closing at 406.400 [3] Net Outflow Ratios - GX China (03040) had a net outflow ratio of -100.00% with a net outflow of -11.4 thousand, closing at 38.140 [3] - Kangji Medical (09997) recorded a net outflow ratio of -60.98% with a net outflow of -20.9363 million, closing at 8.850 [3] - China International Marine Containers (02039) had a net outflow ratio of -48.45% with a net outflow of -16.1516 million, closing at 8.020 [3]

Group 1 - The article provides a ranking of open-end funds based on their net asset value growth as of September 11, 2025, highlighting the top 10 funds with significant increases [2][4]. - The top-performing funds include Huatai-PB Quality Growth Mixed C, Huatai-PB Quality Growth Mixed A, and Zhongjia Core Intelligent Manufacturing Mixed C, among others, with notable net value increases [2][4]. - The article also mentions that a total of 28,679 funds have updated their net values, indicating a comprehensive overview of the fund market [3]. Group 2 - The analysis indicates that the Shanghai Composite Index opened lower but rebounded strongly, with a trading volume of 2.46 trillion, reflecting a positive market sentiment [6]. - Leading sectors include communication equipment, components, and semiconductors, which saw gains exceeding 6%, while tourism, hotel catering, oil, and pharmaceuticals lagged behind [6]. - The fund with the fastest net value growth is identified as Huatai-PB Quality Growth Mixed C, suggesting a strong performance in the current market environment [6].

Summary of Key Points from Conference Call Records Industry Overview - The global pharmaceutical industry is facing a "patent cliff," with over 40% of revenues affected for many multinational companies, creating opportunities for Chinese innovative drug companies to introduce their assets [1][3][4] - The Chinese innovative drug sector is experiencing a diverse globalization path, including overseas expansion, business development, and joint ventures, with significant collaboration with regions like Europe, Southeast Asia, and the Middle East [1][5] Company Performance - **Hengrui Medicine**: Achieved a revenue growth of 15.88% and a net profit growth of 29.67% in the first half of the year, with expectations for further performance improvement in the second half [1][7] - **Kangfang Biotech**: Reported a revenue increase of 49.20% in the first half of the year, with promising data from its API12 presented at WCLC and ongoing global clinical trials for AK104 [1][8] Market Dynamics - The innovative drug sector showed healthy performance in the first half of the year, with significant contributions from products entering the medical insurance list, enhancing profit margins for companies like Kangfang Biotech, Hengrui Medicine, and others [1][6] - The domestic CRO (Contract Research Organization) industry is entering a new phase after adjustments, with a recovery in overseas demand and a clear trend of Chinese innovative drugs moving into late-stage clinical trials [3][10][11] Future Trends and Drivers - The core driving force for Chinese innovative drugs going global is their breakthrough global competitiveness, particularly in next-generation immunotherapy and antibody-drug conjugates (ADCs) [2][12] - The domestic CRO industry is expected to benefit from sustained global innovation demand, increased R&D spending, and the internationalization of Chinese innovative drugs [12] Geopolitical Impact - Geopolitical factors have influenced the Chinese CRO industry, with concerns arising from U.S. regulations, but these have been alleviated over time as companies enhance their core capabilities and expand overseas [13] Notable Companies and Products - **Innovative Products**: - **Sinda's PD-L1 monoclonal antibody**: Demonstrated promising survival data for patients with solid tumors, indicating a broad international market potential [19] - **Gree Pharmaceutical's GLP-1 drugs**: Showed favorable clinical data with significant market potential due to expected weight loss effects [20][21] - **Leading CDMO Companies**: Companies like WuXi AppTec reported a 21% revenue growth and a 102% increase in net profit, benefiting from the ADC industry and overseas expansion [3][14] Conclusion - The Chinese innovative drug sector is poised for growth, driven by strong performance metrics, a favorable global market environment, and strategic international collaborations. The ongoing developments in clinical trials and product launches are expected to further enhance the competitive landscape for these companies [1][9][22][23][24]

Investment Rating - The investment rating for the company is "Buy" (maintained) due to smooth commercialization progress and further updates on HARMONi data [5]. Core Views - The company reported a revenue of 1.412 billion RMB in H1 2025, representing a year-on-year increase of 37.75%, with a net profit attributable to shareholders of -570 million RMB [7]. - The commercialization of key products, namely Cadonilimab and Ivosidenib, has driven revenue growth, with product sales revenue increasing by 49.20% year-on-year [7]. - The HARMONi study presented at the WCLC 2025 conference showed improved overall survival (OS) data, with an OS hazard ratio (HR) of 0.78, indicating significant survival benefits [7]. - The company is expected to achieve revenues of 34.19 billion RMB, 55.98 billion RMB, and 85.77 billion RMB for the years 2025 to 2027, respectively [7]. Financial Summary - Revenue projections for 2023, 2024, 2025E, 2026E, and 2027E are 4,526 million RMB, 2,124 million RMB, 3,419 million RMB, 5,598 million RMB, and 8,577 million RMB, respectively, with corresponding growth rates of 440.3%, -53.1%, 61.0%, 63.7%, and 53.2% [6]. - The net profit attributable to shareholders is projected to be 2,028.30 million RMB in 2023, -514.52 million RMB in 2024, -29.64 million RMB in 2025E, 586.11 million RMB in 2026E, and 1,485.85 million RMB in 2027E, with growth rates of 273.6%, -125.4%, 94.2%, 2077.2%, and 153.5% respectively [6]. - The company's reasonable equity value is estimated at 187.5 billion HKD, assuming a perpetual growth rate of 3% and a WACC of 7.06% [7].

Market Overview - On September 11, the Hang Seng Index fell by 0.43%, closing at 26,086.32 points, while southbound funds through the Stock Connect recorded a net purchase of HKD 18.989 billion [1][3] - The total trading volume for the Stock Connect on September 11 was HKD 172.214 billion, with a net purchase of HKD 18.989 billion [1] Stock Performance - In the Shanghai Stock Connect, the total trading volume was HKD 103.737 billion, with a net purchase of HKD 8.073 billion [1] - In the Shenzhen Stock Connect, the total trading volume was HKD 68.477 billion, with a net purchase of HKD 10.916 billion [1] Active Stocks - The most actively traded stock in the Shanghai Stock Connect was Alibaba-W, with a trading volume of HKD 80.75 billion and a net purchase of HKD 29.46 billion, closing up by 0.35% [1][2] - Meituan-W had the highest net sell amount of HKD 9.36 billion, closing down by 5.06% [1][2] - In the Shenzhen Stock Connect, Alibaba-W also led with a trading volume of HKD 43.575 billion and a net purchase of HKD 7.835 billion [2] - The top net purchase stock was Innovent Biologics, with a net purchase of HKD 0.847 billion, despite closing down by 2.51% [2] Summary of Key Stocks | Stock Code | Stock Name | Trading Volume (HKD million) | Net Purchase (HKD million) | Daily Change (%) | |------------|------------------|------------------------------|----------------------------|-------------------| | 09988 | Alibaba-W | 807.48 | 294.62 | 0.35 | | 03690 | Meituan-W | 618.38 | -93.59 | -5.06 | | 00981 | SMIC | 491.04 | 41.75 | 4.97 | | 01801 | Innovent Biologics| 253.79 | 84.73 | -2.51 | | 00700 | Tencent Holdings | 263.33 | -92.26 | -0.63 | [2]

Market Overview - On September 11, the Hang Seng Index fell by 0.43% with a total southbound trading volume of HKD 172.21 billion, including buy transactions of HKD 95.60 billion and sell transactions of HKD 76.61 billion, resulting in a net buy of HKD 18.99 billion [1] Southbound Trading Activity - The southbound trading through Stock Connect (Shenzhen) had a total trading volume of HKD 68.48 billion, with buy transactions of HKD 39.70 billion and sell transactions of HKD 28.78 billion, leading to a net buy of HKD 10.92 billion [1] - The southbound trading through Stock Connect (Shanghai) had a total trading volume of HKD 103.74 billion, with buy transactions of HKD 55.91 billion and sell transactions of HKD 47.83 billion, resulting in a net buy of HKD 8.07 billion [1] Active Stocks - Alibaba-W was the most actively traded stock with a total trading volume of HKD 124.32 billion and a net buy of HKD 37.30 billion, closing with a price increase of 0.35% [1][2] - Other notable stocks included Meituan-W and SMIC, with trading volumes of HKD 84.52 billion and HKD 80.43 billion, respectively [1] - Tencent Holdings had the highest net sell amount of HKD 11.51 billion, closing down by 0.63% [1][2] Continuous Net Buying and Selling - Alibaba-W and SMIC were the only two stocks with continuous net buying for more than three days, with Alibaba-W having a total net buy of HKD 371.43 billion over 15 days and SMIC with HKD 15.76 billion over 3 days [2] - Stocks with continuous net selling included Kangfang Biotech, Tencent Holdings, and Meituan-W, with total net sell amounts of HKD 17.48 billion, HKD 14.61 billion, and HKD 10.28 billion, respectively [2]